ROCKLATAN Drug Insight

“ROCKLATAN Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about ROCKLATAN for Glaucoma in the 7MM. A detailed picture of the ROCKLATAN for Glaucoma in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the ROCKLATAN for Glaucoma. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ROCKLATAN market forecast, analysis for Glaucoma in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Glaucoma.

Drug Summary

ROCKLATAN (netarsudil and latanoprost ophthalmic solution) is a 0.02%/0.005 fixed-dose combination of a Rho kinase inhibitor and a prostaglandin F2α analog indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. In Europe the drug is sold with trade name ROCLANDA.

ROCKLATAN is the first and only fixed-dose combination product in the United States for the reduction of intraocular pressure that includes a prostaglandin, and the only fixed-dose combination product available in the United States that is dosed once daily.

Dosage

ROCKLATAN is prescribed as one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment is continued with the next dose in the evening.

ROCKLATAN should not be taken more than once per day. ROCKLATAN may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs are administered at least 5 minutes apart.

Mechanism of Action

ROCKLATAN is comprised of two components: netarsudil and latanoprost. Each of these two components decreases elevated IOP. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and glaucomatous visual field loss. It is believed to reduce IOP by increasing the outflow of aqueous humor.

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the ROCKLATAN description, mechanism of action, dosage and administration, research and development activities in Glaucoma.
•  Elaborated details on ROCKLATAN regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the ROCKLATAN research and development activity in Glaucoma in detail across the United States, Europe and Japan.
•  The report also covers the patents information with expiry timeline around ROCKLATAN.
•  The report contains forecasted sales of ROCKLATAN for Glaucoma till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Glaucoma.
•  The report also features the SWOT analysis with analyst views for ROCKLATAN in Glaucoma.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ROCKLATAN Analytical Perspective by DelveInsight

• In-depth ROCKLATAN Market Assessment

This report provides a detailed market assessment of ROCKLATAN in Glaucoma in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

• ROCKLATAN Clinical Assessment

The report provides the clinical trials information of ROCKLATAN in Glaucoma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

•  In the coming years, the market scenario for Glaucoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ROCKLATAN dominance.
•  Other emerging products for Glaucoma are expected to give tough market competition to ROCKLATAN and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ROCKLATAN in Glaucoma.
•  Our in-depth analysis of the forecasted sales data of ROCKLATAN from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ROCKLATAN in Glaucoma.

Key Questions

•  What is the product type, route of administration and mechanism of action of ROCKLATAN?
•  What is the clinical trial status of the study related to ROCKLATAN in Glaucoma and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ROCKLATAN development?
•  What are the key designations that have been granted to ROCKLATAN for Glaucoma?
•  What is the forecasted market scenario of ROCKLATAN for Glaucoma?
•  What are the forecasted sales of ROCKLATAN in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging products available in Glaucoma and how are they giving competition to ROCKLATAN for Glaucoma?
•  Which are the late-stage emerging therapies under development for the treatment of Glaucoma?